Wedbush Starts Aquestive Therapeutics (AQST) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- S&P 500, Nasdaq reach record closing highs as focus pivots to earnings
- Oil prices fall nearly 2% as Middle East supply concerns ease
- U.S. 10-year yield climb revives dotcom-era parallels: UBS weighs in
- Goldman flags 2 key market risks if a climb in yields persists
- Shell CEO says Middle East oil flows reach 80% of prewar levels
Tweet
Share
E-mailGet Alerts AQST Hot Sheet
Price: $4.61 --0%
Rating Summary:
12 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 10 | New: 10
Rating Summary:
12 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 10 | New: 10
Join SI Premium – FREE
Wedbush analyst Liana Moussatos initiates coverage on Aquestive Therapeutics (NASDAQ: AQST) with a Outperform rating and a price target of $33.00.
For an analyst ratings summary and ratings history on Aquestive Therapeutics click here. For more ratings news on Aquestive Therapeutics click here.
Shares of Aquestive Therapeutics closed at $18.28 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Oppenheimer Starts Brown & Brown (BRO) at Outperform
- Barclays Starts Insulet Corporation (PODD) at Equalweight
- Oppenheimer Starts Arthur J. Gallagher (AJG) at Perform
Create E-mail Alert Related Categories
New CoverageRelated Entities
Liana MoussatosSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
